← Back to Screener
CAMP4 Therapeutics Corporation Common Stock (CAMP)
Price$4.51
Favorite Metrics
Price vs S&P 500 (26W)12.28%
Price vs S&P 500 (4W)-19.69%
Market Capitalization$233.12M
All Metrics
Book Value / Share (Quarterly)$0.92
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-2.86%
Cash Flow / Share (Quarterly)$-0.58
Price vs S&P 500 (YTD)-30.89%
Gross Margin (TTM)35.78%
Net Profit Margin (TTM)-7.27%
EPS (TTM)$-2.55
10-Day Avg Trading Volume0.09M
EPS Excl Extra (TTM)$-2.55
Revenue Growth (5Y)-4.22%
EPS (Annual)$-2.67
ROI (Annual)-166.67%
Gross Margin (Annual)36.96%
Net Profit Margin (5Y Avg)-7.07%
Cash / Share (Quarterly)$2.12
Revenue Growth QoQ (YoY)-15.26%
ROA (Last FY)-67.80%
Revenue Growth TTM (YoY)5.57%
EBITD / Share (TTM)$-2.58
ROE (5Y Avg)-18.64%
Operating Margin (TTM)-5.42%
Cash Flow / Share (Annual)$-0.58
P/B Ratio4.86x
P/B Ratio (Quarterly)6.63x
Net Income / Employee (Annual)$-2
Net Interest Coverage (TTM)-2.10x
ROA (TTM)-100.63%
EPS Incl Extra (Annual)$-2.67
Current Ratio (Annual)7.13x
Quick Ratio (Quarterly)7.08x
3-Month Avg Trading Volume0.21M
52-Week Price Return177.16%
Revenue / Employee (TTM)$450,311
Tangible BV / Share (Quarterly)$-2.90
P/S Ratio (Annual)0.05x
Asset Turnover (Annual)0.76x
52-Week High$7.75
Operating Margin (5Y Avg)-1.59%
EPS Excl Extra (Annual)$-2.67
CapEx CAGR (5Y)5.89%
26-Week Price Return21.02%
Quick Ratio (Annual)7.08x
13-Week Price Return-24.16%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)7.13x
Enterprise Value$233.118
Revenue / Share Growth (5Y)-4.22%
Asset Turnover (TTM)0.79x
Book Value / Share Growth (5Y)-41.47%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)8.82x
Pretax Margin (Annual)-10.63%
Cash / Share (Annual)$2.12
3-Month Return Std Dev140.15%
Gross Margin (5Y Avg)39.45%
Net Income / Employee (TTM)$-2
EBITDA CAGR (5Y)-30.38%
EBITDA Interim CAGR (5Y)-22.29%
ROE (Last FY)-166.67%
Net Interest Coverage (Annual)-2.83x
EPS Basic Excl Extra (Annual)$-2.67
Receivables Turnover (TTM)3.97x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-2.55
Receivables Turnover (Annual)4.08x
ROI (TTM)-160.59%
P/S Ratio (TTM)0.05x
Pretax Margin (5Y Avg)-5.59%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$-2.85
Free OCF CAGR (5Y)8.13%
Price vs S&P 500 (52W)142.07%
EPS Growth TTM (YoY)47.80%
Year-to-Date Return-26.75%
5-Day Price Return-3.23%
EPS Normalized (Annual)$-2.67
ROA (5Y Avg)-4.61%
Net Profit Margin (Annual)-11.02%
Month-to-Date Return1.81%
Cash Flow / Share (TTM)$0.03
EBITD / Share (Annual)$-2.61
Operating Margin (Annual)-8.83%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-5.86%
LT Debt / Equity (Quarterly)2157.89x
EPS Basic Excl Extra (TTM)$-2.55
P/B Ratio (Annual)6.63x
Inventory Turnover (TTM)7.17x
Pretax Margin (TTM)-6.83%
Book Value / Share (Annual)$0.92
Price vs S&P 500 (13W)-27.02%
Beta-23.95x
Revenue / Share (TTM)$7.92
ROE (TTM)-160.80%
52-Week Low$1.30
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.25
4.25
4.25
4.25
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
CAMPCAMP4 Therapeutics Corporation Common Stock | 0.05x | 5.57% | 35.78% | — | $4.51 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Camp4 Therapeutics is a clinical-stage biopharmaceutical company developing RNA-based therapeutics to restore protein levels in genetic diseases of the central nervous system and liver. The company's pipeline includes two lead programs, CMP-CPS-001 and CMP-SYNGAP.